Literature DB >> 6255531

Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole.

J R Graybill, D M Williams, E Van Cutsem, D J Drutz.   

Abstract

Combinations of amphotericin B and ketoconazole had an additive effect in vitro against Histoplasma capsulatum and Cryptococcus neoformans; ketoconazole combined with flucytosine exerted an indifferent effect against C. neoformans. In vivo studies in athymic nude (nu/nu) mice and their heterozygous (nu/+) littermates demonstrated that treatment with the ketoconazole-amphotericin B combination resulted in longer survival of mice with cryptococcosis than did treatment with ketoconazole plus flucytosine. However, mice given ketoconazole plus amphotericin B did not survive significantly longer than those given amphotericin B alone (cryptococcosis) or ketoconazole alone (histoplasmosis). Combination chemotherapy with ketoconazole and amphotericin B may offer a modest therapeutic advantage over therapy with either drug alone.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255531     DOI: 10.1093/clinids/2.4.551

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  21 in total

1.  Efficacy of SCH39304 in murine cryptococcosis.

Authors:  B I Restrepo; J Ahrens; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Combination antifungal therapy for the treatment of invasive yeast and mold infections.

Authors:  John W Baddley; Peter G Pappas
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

4.  Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.

Authors:  P Connolly; L J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis.

Authors:  E J Anaissie; R Hachem; N C Karyotakis; A Gokaslan; M C Dignani; L C Stephens; C K Tin-U
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Anna M Schimizzi; Monia Maracci; Daniele Giannini; Flavia Carle; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans.

Authors:  I J Sud; D S Feingold
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

8.  Entry of ketoconazole into Candida albicans.

Authors:  P Boiron; E Drouhet; B Dupont; L Improvisi
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

9.  Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination.

Authors:  M M Albert; J R Graybill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Combined activity of ketoconazole and 5-fluorocytosine on potentially pathogenic yeasts.

Authors:  W H Beggs; G A Sarosi
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.